ITEM 7.01 Regulation FD Disclosure
On April 26, 2021, Becton, Dickinson and Company (“BD”) issued a press release
announcing it submitted a 510(k) premarket notification to the U.S. Food and
Drug Administration for the BD Alaris™ System.
The 510(k) submission is intended to bring the regulatory clearance for the BD
Alaris™ System up to date, implement updated features and address open recall
issues, including through a new version of BD Alaris™ System software that will
provide clinical, operational and cybersecurity updates.
The press release is attached as Exhibit 99.1. The information in this Item 7.01
and in Exhibit 99.1 to this Current Report on Form 8-K is being furnished and
shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities thereof, nor shall it be incorporated by reference into future
filings by BD under the Exchange Act or under the Securities Act of 1933, as
amended, except to the extent specifically provided in any such filing.
ITEM 9.01 Financial Statements and Exhibits.
Exhibit 99.1 Press release dated April 26, 2021, which is furnished
pursuant to Item 7.01.
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL
© Edgar Online, source Glimpses